Keytruda shows unprecedented results in lung cancer

In the largest study to date using immunotherapy to treat lung cancer, a new study led by JCCC’s Dr. Edward Garon has found that pembrolizumab (Keytruda), recently approved by the U.S. Food & Drug Administration to treat melanoma, is safe and effective in arresting tumor growth in patients with advanced non-small cell lung cancer. Garon presented results of the potentially game-changing research at the AACR Annual Meeting last month. Read more >

Women with inherited KRAS-variant mutation may be at increased breast cancer risk

In findings that run contrary to some past research suggesting that women on combination hormone replacement therapy are more likely to develop breast cancer, UCLA researchers have discovered that for women with a relatively common inherited mutation known as the KRAS-variant, abrupt lowering of estrogen may increase their breast cancer risk and impact breast cancer biology. Led by JCCC’s Dr. Joanne Weidhaas, the study also found that women with the KRAS-variant are more likely to develop a second primary breast cancer independent of a first breast cancer. Read more >

Wally’s 23rd Annual Grande Marque Champagne Tasting

On Sunday, June 7, 2015, sip champagne while supporting the JCCC at Wally’s 23rd Annual Grande Marque Champagne Tasting, held at Le Merigot Hotel in Santa Monica. Enjoy more than 50 Grande Marque Champagnes, along with signature dishes from over 20 leading restaurants including Angelini Osteria, Bouchon Beverly Hills, Drago Centro and Mélisse at one of the Southland’s top wine and food events of the year. Advance tickets are $175 per person, or $225 per person at the door. Purchase your tickets today!

Keytruda shown to improve response to tumors, extend lives of people with advanced melanoma

A team of international researchers led by JCCC’s Dr. Antoni Ribas has found that the breakthrough immunotherapy drug Keytruda performs better than the current standard of care ipilimumab (Yervoy) for people with advanced melanoma. Study findings showed that the drug significantly improved progression-free survival and overall patient survival compared to ipilimumab, and researchers hope the findings will encourage the FDA to designate Keytruda as a first-line therapy for patients with metastatic melanoma.
Social Networking Tools
- JCCC is on Twitter, Facebook and YouTube. Learn how to follow us and stay connected!

In memory: research pioneer Carol Kruse

Join us in mourning Carol Kruse, a JCCC member and recognized leader in the field of brain cancer research, who recently passed after a long battle with an aggressive form of cancer. At the time of her passing, she was working on better understanding the immune-resistance mechanisms used by tumor cells to facilitate the development of alternative therapies for treating patients with primary malignant brain tumors. She is survived by her husband and three children.

Read more >